Vasomotor Symptoms in a Woman with a Prior Unprovoked DVT
Rosalind, 52, has not had a period in 15 months. She reports 8-10 moderate-to-severe hot flashes daily with drenching night sweats and sleep broken three or four nights a week; her PHQ-2 is 2 and her Menopause Rating Scale score is 22. BMI is 27, she does not smoke, and she exercises twice weekly. At 44 she had an unprovoked left popliteal DVT treated with 6 months of apixaban and no recurrence since. Her mother was diagnosed with breast cancer at 71. She has an intact uterus, a normal mammogram 4 months ago, and unremarkable CBC, TSH, and lipids. She comes in asking for 'the hormone patch my sister uses' but says she will accept anything that lets her sleep.
1. How do you counsel her about hormone therapy given her VTE history? State what you would recommend and what you would not, with your reasoning.
Read the worked answer
Frame it as a shared decision, not a reflex prescription.
- Prior unprovoked VTE is a relative (Category 3) contraindication to hormone therapy. Oral estrogen roughly doubles to triples VTE risk in the general population, and what drives that risk is the oral route - first-pass hepatic metabolism raises clotting factors - along with dose.
- Low-dose transdermal estradiol does not appear to increase VTE risk in observational data and is the preferred route for women with thrombotic or metabolic risk factors. That does not make it risk-free, and expert opinion is not unanimous.
- Her mother's breast cancer at 71 is not a contraindication. The elevated risk associated with hormone therapy is essentially confined to current users and is small; confirm she has no personal breast symptoms and keep mammography current.
What I would recommend: a hematology consultation, or at minimum a documented risk conversation, followed by low-dose transdermal estradiol with micronized progesterone. Never estrogen alone in a woman with a uterus.
What I would not do: oral conjugated equine estrogen or an oral estradiol-progestin combination, and not a compounded pellet whose dose cannot be titrated downward if problems arise.
2. If she and her hematologist agree to proceed, write the specific regimen and monitoring plan, including endometrial protection.
Read the worked answer
Regimen:
- Estradiol transdermal patch 0.05 mg/day, changed twice weekly; reassess at 8-12 weeks and titrate to the lowest dose that controls symptoms (0.075-0.1 mg/day if needed).
- Micronized progesterone 100 mg orally at bedtime nightly - provides endometrial protection and often improves sleep, which is her main complaint.
Alternative endometrial protection: a 52-mg levonorgestrel IUD is equally acceptable and attractive if she also wants contraception or has heavy bleeding, but it adds an insertion procedure in a woman who is already postmenopausal.
Monitoring and safety plan:
- Symptom diary and a visit at 8-12 weeks; reassess the need for therapy at least annually.
- Blood pressure and weight at each visit; transdermal estrogen can produce a small rise, so re-evaluate if it is notable.
- Any vaginal bleeding after 6 months of therapy, or heavy bleeding at any point, requires transvaginal ultrasound and endometrial biopsy.
- Teach VTE red flags - unilateral leg swelling, pleuritic chest pain, sudden dyspnea - and instruct her to stop the patch and seek care.
- Continue age-appropriate mammography and cervical screening, and do not attribute new symptoms to 'just hormones' without evaluating them.
3. She asks what happens if hormones are off the table. What non-hormonal options would you offer, and how do you prioritize them?
Read the worked answer
Non-hormonal options, in the order I would offer them:
- Cognitive behavioral therapy and clinical hypnosis - both have trial evidence comparable to low-dose hormone therapy for hot flashes; refer to an app-based or group program, which also suits her sleep complaint.
- Escitalopram 10 mg daily (up to 20 mg) or venlafaxine 37.5-75 mg daily - SSRIs and SNRIs reduce hot flashes by roughly 50-60%. Avoid paroxetine in any woman who might later take tamoxifen.
- Gabapentin 300 mg at bedtime, titrating toward 900 mg - particularly useful here because her chief complaint is sleep disruption.
- Fezolinetant 45 mg daily if the above fail - an NK3 receptor antagonist requiring a baseline liver panel and monitoring, contraindicated in cirrhosis.
- Oxybutynin 2.5-5 mg twice daily as a later option, with attention to anticholinergic effects.
Layer in lifestyle measures: layered clothing, a cool bedroom, avoiding alcohol and late caffeine, weight management, and structured sleep hygiene.
Also: her PHQ-2 of 2 is below the screening cutoff, but she carries a heavy symptom burden with chronic sleep fragmentation. Rescreen for depression and anxiety if mood symptoms emerge, and treat insomnia in its own right rather than assuming it will resolve with hot-flash control.